Haemonetics (STU:HAZ) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 01, 2026)


STU:HAZ Haemonetics Corp STU:HAZ
25 GF Score
Price €65.50
GF Value €74.16
! 4 Warning Signs
View Full Analysis

What is Haemonetics Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Haemonetics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

STU:HAZ vs ITGR, IRTC, ESTA: Margin of Safety % (DCF Earnings Based) Comparison

For the Medical Devices subindustry, Haemonetics's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Haemonetics Margin of Safety % (DCF Earnings Based) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Haemonetics's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Haemonetics's Margin of Safety % (DCF Earnings Based) falls into.


STU:HAZ
25GF Score
Haemonetics Corp STU:HAZ
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Haemonetics (STU:HAZ) Overvalued in 2026?

Based on GuruFocus' analysis, Haemonetics stock appears to be undervalued. The current stock price of €65.50 is trading 11.7% below its estimated GF Value™ of €74.16.

Key valuation signals for STU:HAZ:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €74.16 vs. price of €65.50 (11.7% below fair value)
  • GF Score™: 25/100 with 4 warning signs

No single metric tells the full story. See the STU:HAZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Haemonetics Business Description

Other Exchanges HAE:USA
Address 125 Summer Street, Boston, MA, USA, 02110
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
25GF Score

Get the complete analysis for STU:HAZ

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€65.50
Price
€74.16
GF Value